Redeye shares its initial take on BONESUPPORT's Q3 2026 report.
* Net sales SEK 616m, -1% vs ABGSCe and Factset cons.
* Q3 sales 6% above our ests. at SEK 260m, for 20% org.
Redeye shares its initial take on XVIVO’s Q3 2026 report.
Verkkokauppa.com sales grew by 2.1% y/y, missing the consensus expectation of 4.
Ahead of Relais' Q3 results, we take a more cautious near-term view, given the changes in fuel price...
In this interview, Physitrack’s CEO Henrik Molin talks about the Q3 2026 report.
Base Case lowered to SEK80.5 (86), mainly on a higher WACC and lower Consulting and Systems estimate...
* Sequential sales decline, but order activity has improved * We lift '26e/'27e/'28e EBIT by 9%/7%/6...
* Q3e sales +6%, with 5% organic growth * Raised EBITA driven by new contracts * Share trading at 15...
Redeye comments on q.beyond's preliminary Q3 2026 figures and second guidance cut in three months.
* Q3e: sequential step-up in organic growth and margin * M&A the main driver behind our EBITA upgrad...
Ahead of Q3 results on 4 November, we raise FY26 EBITDA to € 74.
VERBIO is set for a strong start to FY26/27, with Q1'26/27 EBITDA expected to quadruple yoy to € 61.
* Sales SEK 38m (vs. ABGSCe 30m), incl. SEK 9m recycled metal sales * HJWAVE IC500 delivered in Q3, ...
Redeye comments on Litium's Q3 report, which came in line with our expectations on both ARR and net ...
Redeye comments on Dynavox's Q3 report released earlier this morning.
Redeye updates on EG7 ahead of Q3-results (due 10 November).
Redeye trims its forecast following Q3’26 figures, which posted healthy progress although somewhat b...
Ahead of NoHo Partners' Q3 2026 report, due on 3 November, we make small negative estimate revisions...